Point mutations in BRAF, mostly resulting by the substitution of valine for glutamin acid at codon 600 (VAL600 Glu or V600E) but also NRAS are the most frequent activating somatic events in melanoma and have been extensively studied in large cohorts of clinical trials for their impact on disease progression and therapeutic intervention [13,23,38,39,40,41]. The gene discussed is NRAS; the disease is melanoma.